Cell therapy biodistribution and efficacy assessment using a highly sensitive spatial multiomics assay

Cell therapies such as CAR-T therapies and TCR T cell therapies have proven to be highly effective in treating hematologic malignancies, and major efforts are being made to achieve similar efficacy in solid tumors as well as for autoimmune disorders.

Here, we demonstrate the use of the new RNAscope™ Multiomic LS assay on the BOND Rx that can detect up to 6 RNA and protein targets on the same slide. The TSA-based amplification strategy offers signal boost for both RNA and protein targets. The workflow is completely protease-free there by preserving antigen integrity and tissue morphology.

Infiltrating cytotoxic T cell lymphocytes were detected using CD8, GZMB and IFNG co-expression in human cervical, breast and colon cancer tissues. In the same tissues, regulatory T cells were detected using CD4, FOXP3 co-expression. PanCK was used as a tumor marker to delineate tumor from stroma. In the NHP model, the distribution of the mRNA in tissues was able to be differentiated as on-target (in hematopoietic or T cells) or off target (tissue parenchyma). The protease-free RNAscope Multiomic LS assay was successfully able to interrogate different subpopulation of immune cells with high fidelity RNA and protein signal while maintaining tissue morphology.

This poster was presented at the ASGCT 2025 meeting.